Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan

A method of treating locally advanced or metastatic breast cancer in a patient, comprising administering to the patient having locally advanced or metastatic breast cancer an effective amount of (a) 4-iodo-3-nitrobenzamide or a metabolite thereof or a pharmaceutically acceptable salt thereof, and (b) irinotecan or a pharmaceutically acceptable salt thereof, wherein the method comprises at least one cycle, wherein the cycle is a period of 21 days, wherein 4-iodo-3-nitrobenzamide or the pharmaceutically acceptable salt thereof is administered at about 8 mg/kg twice weekly for two weeks of the cycle, and wherein irinotecan or a pharmaceutically acceptable salt thereof is administered at about 80 mg/m2 to about 125 mg/m2 once weekly for two weeks of the cycle.

A kit for treating a patient with breast cancer brain metastasis comprising (a) 4-iodo-3-nitrobenzamide or a metabolite thereof or a pharmaceutically acceptable salt thereof, and (b) irinotecan or a pharmaceutically acceptable salt thereof, wherein the breast cancer is ER-negative, PR-negative, and HER2-nonoverexpressing.

A kit comprising (a) 4-iodo-3-nitrobenzamide or a metabolite thereof or a pharmaceutically acceptable salt thereof, and (b) a package insert or label containing instructions for using an effective amount of 4-iodo-3-nitrobenzamide or a metabolite thereof or a pharmaceutically acceptable salt thereof, in combination with irinotecan or a pharmaceutically acceptable salt thereof to treat a patient with breast cancer brain metastasis, wherein the breast cancer is ER-negative, PR-negative, and HER2-nonoverexpressing.

A kit for treating locally advanced or metastatic breast cancer in a patient comprising (a) 4-iodo-3-nitrobenzamide or a metabolite thereof or a pharmaceutically acceptable salt thereof, (b) irinotecan or a pharmaceutically acceptable salt thereof, and (c) a package insert or label containing instructions for using 4-iodo-3-nitrobenzamide or a metabolite thereof or a pharmaceutically acceptable salt thereof, and irinotecan or a pharmaceutically acceptable salt thereof to treat locally advanced or metastatic breast cancer in the patient, wherein the treatment comprises at least one cycle, wherein the cycle is a period of 21 days, wherein 4-iodo-3-nitrobenzamide or the pharmaceutically acceptable salt thereof is administered at about 8 mg/kg twice weekly for two weeks of the cycle, and wherein irinotecan or a pharmaceutically acceptable salt thereof is administered at about 80 mg/m2 to about 125 mg/m2 once weekly for two weeks of the cycle.

A kit comprising (a) 4-iodo-3-nitrobenzamide or a metabolite thereof or a pharmaceutically acceptable salt thereof, and (b) a package insert or label containing instructions for using 4-iodo-3-nitrobenzamide or a metabolite thereof or a pharmaceutically acceptable salt thereof, in combination with irinotecan or a pharmaceutically acceptable salt thereof to treat locally advanced or metastatic breast cancer in a patient, wherein the treatment comprises at least one cycle, wherein the cycle is a period of 21 days, wherein 4-iodo-3-nitrobenzamide or the pharmaceutically acceptable salt thereof is administered at about 8 mg/kg twice weekly for two weeks of the cycle, and wherein irinotecan or a pharmaceutically acceptable salt thereof is administered at about 80 mg/m2 to about 125 mg/m2 once weekly for two weeks of the cycle.